

## Special Issue

# Tumor Microenvironment: Cellular Dynamics, Molecular Players, and Mechanisms of Therapy Resistance

### Message from the Guest Editors

The tumor microenvironment (TME) is a dynamic ecosystem where cancer cells interact with stromal, vascular, and immune populations through cytokines, chemokines, growth factors, extracellular vesicles, and matrix-remodeling enzymes. These interactions activate signaling pathways that drive tumor progression, immune evasion, metabolic adaptation, and therapy resistance across multiple modalities. Deciphering these mechanisms is crucial for understanding how tumors adapt under therapeutic pressure and for identifying exploitable vulnerabilities. For this Special Issue, we invite original research and comprehensive reviews on the cellular dynamics and molecular players of the TME, with particular focus on pathways underlying therapeutic resistance. Contributions featuring systems biology, omics-driven insights, and translational approaches to reprogram the TME or enhance treatment efficacy are especially welcome. By integrating mechanistic insights into innovative strategies, this Special Issue aims to advance next-generation cancer therapies.

---

### Guest Editors

Dr. Teresa Gagliano  
Dr. Angeliki Ditsiou  
Dr. Viviana Vella

---

### Deadline for manuscript submissions

31 December 2026



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/252750](https://mdpi.com/si/252750)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)